What is Zacks Research's Forecast for CVSA Q3 Earnings?

Key Points

• Zacks Research raised its Q3 2027 EPS forecast for Adtalem Global Education to $2.35 from $2.13. Its FY2027 estimate is $8.98 per share, broadly aligned with the company’s FY2027 guidance of $8.90–$9.15.
• Adtalem recently reported quarterly EPS of $2.09, beating the $1.90 consensus estimate by $0.19, while revenue totaled $501.38 million.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $155, compared with the stock’s recent price of $132.55; insiders have sold shares worth about $3.47 million over the past three months.

Adtalem Global Education Inc. (NYSE:CVSA - Free Report) - Analysts at Zacks Research upped their Q3 2027 EPS estimates for Adtalem Global Education in a report issued on Thursday, August 20th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $2.35 for the quarter, up from their prior estimate of $2.13. The consensus estimate for Adtalem Global Education's current full-year earnings is $9.00 per share. Zacks Research also issued estimates for Adtalem Global Education's FY2027 earnings at $8.98 EPS.

Other research analysts also recently issued reports about the company. Weiss Ratings reiterated a "hold (c+)" rating on shares of Adtalem Global Education in a report on Wednesday. Wall Street Zen upgraded Adtalem Global Education from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Truist Financial raised their price objective on Adtalem Global Education from $130.00 to $140.00 and gave the company a "buy" rating in a research report on Monday, May 11th. Finally, Barrington Research reiterated an "outperform" rating and issued a $170.00 target price on shares of Adtalem Global Education in a research note on Monday, June 8th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Adtalem Global Education presently has a consensus rating of "Moderate Buy" and an average target price of $155.00.

Adtalem Global Education Stock Up 0.2%

Adtalem Global Education stock opened at $132.55 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09 and a current ratio of 1.09. The stock has a market capitalization of $4.51 billion, a price-to-earnings ratio of 18.83, a P/E/G ratio of 0.98 and a beta of 0.62. The business's fifty day moving average is $125.54. Adtalem Global Education has a twelve month low of $86.97 and a twelve month high of $156.26.

Adtalem Global Education (NYSE:CVSA - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.90 by $0.19. The company had revenue of $501.38 million for the quarter. Adtalem Global Education had a net margin of 12.87% and a return on equity of 20.88%. Adtalem Global Education has set its FY 2027 guidance at 8.900-9.150 EPS.

Insiders Place Their Bets

In other news, CEO Stephen W. Beard sold 3,545 shares of the firm's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $130.34, for a total value of $462,055.30. Following the completion of the sale, the chief executive officer owned 415,197 shares of the company's stock, valued at $54,116,776.98. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Robert J. Phelan sold 2,900 shares of the business's stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $135.41, for a total value of $392,689.00. Following the transaction, the chief financial officer owned 52,906 shares in the company, valued at approximately $7,164,001.46. This trade represents a 5.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 25,951 shares of company stock valued at $3,470,783. 2.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Adtalem Global Education

An institutional investor recently bought a new position in Adtalem Global Education stock. Kendall Capital Management purchased a new position in shares of Adtalem Global Education Inc. (NYSE:CVSA - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,622 shares of the company's stock, valued at approximately $1,449,000. 98.84% of the stock is owned by institutional investors.

Adtalem Global Education News Roundup

Here are the key news stories impacting Adtalem Global Education this week:

• Positive Sentiment: Zacks Research introduced a FY2029 EPS estimate of $11.53, indicating expected earnings growth from its $8.99 current-year consensus estimate. Its FY2028 forecast of $9.94 also remains above the current-year outlook.
• Neutral Sentiment: The revisions came from Zacks Research and do not represent a change to the broader consensus estimate for Adtalem’s current fiscal year, which remains $8.99 per share.
• Negative Sentiment: Zacks reduced EPS forecasts across multiple periods: Q1 2027 to $1.97 from $2.00, Q2 2027 to $2.38 from $2.51, Q4 2027 to $2.28 from $2.29, Q1 2028 to $2.30 from $2.33, Q2 2028 to $2.56 from $2.68, Q3 2028 to $2.50 from $2.53, and Q4 2028 to $2.59 from $2.63. Zacks also lowered its FY2028 forecast to $9.94 from $10.16, signaling somewhat softer projected profitability.

About Adtalem Global Education

Adtalem Global Education NYSE: CVSA is a provider of higher education and workforce solutions focused primarily on programs that prepare students for professional careers in healthcare, medicine, veterinary medicine and related fields. The company operates campus-based and online degree programs, continuing professional education, clinical training and exam-preparation offerings designed to support students seeking licensure and employment in regulated professions.

Adtalem’s portfolio includes institution brands that deliver undergraduate, graduate and professional training across nursing, medicine, veterinary medicine and allied health disciplines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source